Trial reportClinical neuroradiology2026
Brain Atrophy and White Matter Changes Grading Agreement on NCCT and MRI in Ischemic Stroke.
Trial report in Clinical neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBrain frailty measures like atrophy and white matter changes (WMC) are becoming increasingly relevant in stroke outcome prediction but are conventionally thought to be best seen on MRI compared to CT. We assessed agreement between baseline CT vs follow-up MRI ratings for brain atrophy and WMC; and compared their discriminative ability for 90-day functional outcomes in acute ischemic stroke.
methodsIn this post-hoc, observational analysis of baseline CT and follow-up MRI data from the Alteplase compared to Tenecteplase (AcT) randomised-controlled trial, experts assessed brain atrophy, periventricular and deep WMC using established visual-rating scales. Binary agreement (none-mild vs. moderate-severe) and agreement across the full scores between atrophy and WMC measures on CT and MRI were calculated using Gwet's agreement coefficient (AC1). Logistic regression estimated discrimination for 90-day modified Rankin Scale (mRS) 0-1. Agreement of AUCs for CT and MRI models were compared using DeLong's test.
resultsAmong 1577 AcT participants, 491(31.1%) had interpretable CT and MRI. Binary agreement was substantial for periventricular (AC1 = 0.70) and total WMC (AC1 = 0.68) scores, Koedam scale (AC1 = 0.76) and frontal atrophy (AC1 = 0.80). Almost perfect agreement (AC1:0.81-0.97) was found for deep WMC (AC1 = 0.85), and the other atrophy scores (AC1 = 0.81-0.97). There was no significant difference between NCCT or MRI in discriminating 90-day mRS 0-1 for any measures.
conclusionsCT ratings of brain atrophy and WMC by experts have substantial to almost-perfect agreement compared to MRI. Both achieve similar discrimination of 90-day functional outcomes. This implies the reasonable use of CT scans in evaluating brain frailty measures in clinical practice and stroke trials.
Indexed as
Identifiers
41758218What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.